AAV vectors: Is clinical success on the horizon?

Gene Therapy

Volumn 7, Issue 1, 2000, Pages 24-30

  Monahan, P E ^a,b   Samulski, R J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Division of Hematology/Oncology   (United States)

Author keywords

AAV; Adeno associated virus; Gene therapy; Viral vectors

Indexed keywords

VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; EXPRESSION VECTOR; GENE CASSETTE; GENE THERAPY; GENE TRANSFER; HUMAN; IMMUNE RESPONSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSGENE; VIRUS TITRATION;

ADENO-ASSOCIATED VIRUS; DNA VIRUSES;

EID: 0033978147     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301109     Document Type: Review

References (48)

1. McKeon C, Samulski R. NIDDK Workshop on AAV vectors: gene transfer into quiescent cells. Hum Gene Ther 1996; 7: 1615-1619.
2. LaFace D et al. Gene transfer into hematopoietic progenitor cells mediated by an adeno-associated virus vector. Virology 1988; 162: 483-486.
3. Xiao X, Li J, Samulski R. Efficient long term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996; 70: 8098-8108.
4. Kessler PD et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 1996; 93: 14082-14087.
5. Grimm D, Kleinschmidt J. Progress in adeno-associated virus type 2 vector production: promises and prospects for clinical use. Hum Gene Ther 1999; 10: 2445-2450.
6. Zolotukhin S et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Therapy 1999; 6: 973-985.
7. Clark K et al. Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type virus. Hum Gene Ther 1999; 10: 1031-1039.
8. Summerford C, Samulski R. Viral receptors and vector purification: new approaches for generating clinical-grade reagents. Nature Med 1999; 5: 587-588.
9. Grimm D et al. Titration of AAV-2 particles via a novel capsid ELISA: packaging of genomes can limit production of recombinant AAV-2. Gene Therapy 1999; 6: 1322-1330.
10. Samulski RJ, Sally M, Muzyczka N. Adeno-associated viral vectors. In: Friedman T (ed). The Development of Human Gene Therapy. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1999, pp 131-172.
11. Qing K et al. Human fibroblast growth factor receptor 1 is a coreceptor for infection by adeno-associated virus 2. Nature Med 1999; 5: 71-77.
12. Liu Y et al. Transduction and utility of the granulocyte-macrophage colony-stimulating factor gene into monocytes and dendritic cells by adeno-associated virus. J Interfer Cytokine Res 1999 (in press).
13. Gao G et al. High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus. Hum Gene Ther 1998; 9: 2353-2362.
14. Conway J et al. High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type 1 vector expressing AAV-2 Rep and Cap. Gene Therapy 1999; 6: 986-993.
15. Ding L, Lu S, Munshi N. In vitro packaging of an infectious recombinant adeno-associated virus 2. Gene Therapy 1997; 4: 1167-1172.
16. Zhou X, Muzyczka N. In vitro packaging of adeno-associated virus DNA. J Virol 1998; 72: 3241-3247.
17. Nakai H et al. Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood 1998; 91: 4600-4607.
18. Snyder RO et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nature Med 1999; 5: 64-70.
19. Wang L et al. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci USA 1999; 96: 3906-3910.
20. Song S et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors. Proc Natl Acad Sci USA 1998; 95: 14384-14388.
21. Pruchnic R et al. The use of adeno-associated virus to circumvent the maturation dependent viral transduction of myofibers. Hum Gene Ther 1999 (accepted).
22. Chiorini J et al. Cloning and characterization of adeno-associated virus type 5. J Virol 1999; 73: 1309-1319.
23. Rabinowitz J, Xiao W, Samulski R. Insertional mutagenesis of AAV2 capsid and the protection of recombinant virus. Virology 2000: (in press).
24. Girod A et al. Genetic capsid modifications allow efficient retargeting of adeno-associated virus type 2. Nature Med 1999; 5: 1052-1056.
25. Ponnazhagan S et al. Recombinant human parvovirus B19 vectors: erythroid cell-specific delivery and expression of transduced genes. J Virol 1998; 72: 5224-5230.
26. Chao H et al. Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood 2000 (in press).
27. Zhang L et al. Efficient expression of CFTR function with adeno-associated vectors that carry shortened CFTR genes. Prof Natl Acad Sci USA 1998; 95: 10158-10163.
28. Sun L, Li J, Xiao X. Overcoming AAV vector size limitation through viral DNA hetero-dimerization. 1999 (submitted).
29. Yang J et al. Concatamerization of adeno-associatcd virus circular genomes occurs through intermolecular recombination. J Virol 1999; 73: 9468-9477.
30. Fisher KJ et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nature Med 1997; 3: 306-312.
31. Jooss K et al. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J Virol 1998; 72: 4212-4223.
32. Brockstedt D et al. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. J Appl Biomaterials 1999; 92: 67-75.
33. Manning W et al. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D. J Virol 1997; 71: 7960-7962.
34. Hemandez Y et al. Latent adeno-associatcd virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J Virol 1999; 73: 8549-8558.
35. Russell D, Kay M. Adeno-associated virus vectors and hematology. Blood 1999; 94: 864-874.
36. Chirmule N et al. Immune responses to adenovirus and adeno-associatcd virus in humans. Gene Therapy 1999; 6: 1574-1583.
37. Xiao W et al. Gene therapy vectors based on adeno-associated virus type 1. J Virol 1999; 73: 3994-4003.
38. Rutledge E, Halbert C, Russell D. Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol 1998; 72: 309-319.
39. Muramatsu S et al. Nucleotide sequencing and generation of an infectious clone of adeno-associated virus 3. Virology 1996; 221: 208-217.
40. Bohl D et al. Control of erythopoietin by doxycycline in mice after intramuscular injection of adeno-associated vector. Blood 1998; 92: 1512-1517.
41. Zhou S et al. Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primates. Gene Therapy 1998; 5: 665-670.
42. Frisella Jr W et al. Direct intracranial injection of recombinant adeno-associated virus at birth corrects lysosomal storage and improves cognitive function in the mucopolysaccharidosis VII mouse. American Society of Gene Therapy, 2nd Annual Meeting, Washington, DC, 1999, 12a (Abstr. 43).
43. Lewin A et al. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nature Med 1998; 4: 967-971.
44. Conrad C et al. Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR in the primate lung. Gene Therapy 1996; 3: 658-668.
45. Beck S et al. Repeated delivery of adeno-associated virus vectors to the rabbit airway. J Virol 1999; 73: 9446-9455.
46. Wagner J et al. Efficient and persistent gene transfer of AAV-CFTR in maxillary sinus. Lancet 1998; 351: 1702-1703.
47. Chao HJ et al. Persistent expression of canine factor IX in hemophilia B canines. Gene Therapy 1999; 6: 1695-1704.
48. Herzog RW et al. Long-term correction of canine hemophilia B by gene therapy of blood coagulation factor IX mediated by adeno-associated viral vector. Nature Med 1999; 5: 56-63.